Last reviewed · How we verify
NCT05549427: VAP-MDR
Ventilator Associated Pneumonia by Multi-Drug Resistant Organism
trial testing Ventilation in Ventilator Associated Pneumonia in 319 participants. Completed in 17 August 2022.
17 August 2022
Quick facts
| Lead sponsor | Sultan Qaboos University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 319 |
| Start date | 9 June 2022 |
| Primary completion | 17 August 2022 |
| Estimated completion | 17 August 2022 |
| Sites | 1 location across Oman |
Drugs / interventions tested
- Ventilation
Conditions studied
- Ventilator Associated Pneumonia — all drugs for Ventilator Associated Pneumonia →
- Multi-antibiotic Resistance — all drugs for Multi-antibiotic Resistance →
Sponsor
Sultan Qaboos University
Who can join
13 and older, any sex, with Ventilator Associated Pneumonia or Multi-antibiotic Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Ventilator-associated pneumonia (VAP) is an infection of the pulmonary parenchyma in patients exposed to invasive mechanical ventilation for at least 48 h and is part of ICU-acquired pneumonia. VAP is one of the most frequent ICU-acquired infections. Reported incidences vary widely from 5 to 40%, depending on the setting and diagnostic criteria. The estimated attributable mortality of VAP is around 10%. Investigators will focus this study on the current understanding of the epidemiology and treatment of VAP caused by multi-drug resistant (MDR) organisms. The MDR organisms are significant threats to the prognosis of the ICU patient. They are challenging to treat because of a limited number of newer antibiotics available for treatment. Understanding their distribution and sensitivity pattern may provide clues on how to deal with this significant problem. The current study examines the distribution of MDR organisms in VAP and its incidence and outcome. Investigators will also study the sensitivity pattern of these MDR organisms and how it affects the patient outcome. All patients admitted to adult ICU will be scanned, positive respiratory cultures will be noted, and those with VAP will be studied in detail. Patient data will be collected using the hospital information system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05549427
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ventilation
Trials testing the same drug.
- NCT05018468 — Quality of Ventilation With Facial Versus Nasal Mask vs Nasal Mask Anesthesia in Children 3 to 12 Years Old · NA · completed
- NCT03741790 — Airway Management of Pediatric Patients With Klippel-Feil Syndrome · active not recruiting
Other recruiting trials for Ventilator Associated Pneumonia
Currently open trials in the same condition.
- NCT07102407 — Effect of a Constructivist Educational Program on Preventing Ventilator-Associated Pneumonia in Intensive Care Units · NA · recruiting
- NCT06554327 — Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens · NA · recruiting
- NCT05591924 — Early Severe Illness TrAnslational BioLogy InformaticS in Humans · recruiting
- NCT06092554 — Probiotics to Actively Counter Ventilator Associated Pneumonia (PROACT) · NA · recruiting
- NCT05979545 — EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics · Phase 4 · recruiting
Other Sultan Qaboos University trials
Trials by the same sponsor.
- NCT07474077 — Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients U · Phase 3 · not yet recruiting
- NCT07320248 — Virtual Reality for Patient Preparation Before Cardiac Catheterization in Oman · NA · not yet recruiting
- NCT07427134 — Pediatric Insulin Plan Calculator for T1DM Management · NA · not yet recruiting
- NCT06951451 — Effect of Smartphone Application (MED-AD) on Medication Adherence Among Patients With Cardiovascular Disease in Oman · NA · not yet recruiting
- NCT07460570 — Nurse-Led Culturally Adapted Palliative and End-of-Life Training for Oncology Nurses in Oman · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05549427 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sultan Qaboos University
- Last refreshed: 30 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05549427.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing